

Low Molecular Weight Amidoximes that Act as Potent Inhibitors of Lysine-Specific Demethylase 1


Stuart Hazeldine,[†] Boobalan Pachaiyappan,[§] Nora Steinbergs,[‡] Shannon Nowotarski,[‡] Allison S. Hanson,[†] Robert A. Casero, Jr.,[‡] and Patrick M. Woster^{*,§}

[†]Department of Pharmaceutical Sciences, Wayne State University, 259 Mack Avenue, Detroit, Michigan 48202, United States

[‡]Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231, United States

[§]Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, 70 President Street, Charleston, South Carolina 29425, United States

S Supporting Information



ABSTRACT: The recently discovered enzyme lysine-specific demethylase 1 (LSD1) plays an important role in the epigenetic control of gene expression, and aberrant gene silencing secondary to LSD1 dysregulation is thought to contribute to the development of cancer. We reported that (bis)guanidines, (bis)biguanides, and their urea- and thiourea isosteres are potent inhibitors of LSD1 and induce the re-expression of aberrantly silenced tumor suppressor genes in tumor cells in vitro. We now report a series of small molecule amidoximes that are moderate inhibitors of recombinant LSD1 but that produce dramatic changes in methylation at the histone 3 lysine 4 (H3K4) chromatin mark, a specific target of LSD1, in Calu-6 lung carcinoma cells. In addition, these analogues increase cellular levels of secreted frizzled-related protein (SFRP) 2, H-cadherin (HCAD), and the transcription factor GATA4. These compounds represent leads for an important new series of drug-like epigenetic modulators with the potential for use as antitumor agents.

INTRODUCTION

Chromatin architecture is a key determinant in the regulation of gene expression and is strongly influenced by post-translational modification of histones.^{1,2} Histones, which are the chief protein component of chromatin, are complex macromolecules comprised of core protein subunits termed H_{2a}, H_{2b}, H₃, and H₄. Histone tails, consisting of up to 40 amino acid residues, protrude through the DNA strand, and lysines, arginines, serines, threonines, and tyrosines on this tail act as sites for post-translational modification. These modifications, including methylation, ubiquitination, sumoylation, ADP-ribosylation, and acetylation of histone lysine residues and phosphorylation of histone serine, threonine, and tyrosine,³ allow alteration of higher-order nucleosome structure and thus contribute to structural changes in chromatin.^{4,5} In cancer, DNA promoter CpG island hypermethylation in combination with other chromatin modifications, including decreased activating marks and increased repressive marks on histone proteins 3 and 4, have been associated with the silencing of tumor suppressor genes.^{6,7}

Histone lysine methylation/demethylation represents a critical epigenetic modification cycle,^{5,8,9} and dysregulation of this cycle can lead to aberrant silencing of tumor suppressor genes. Histone lysine methylation has been shown to be a dynamic process regulated by the addition of methyl groups by a number of specific histone methyltransferases and removal of methyl groups from mono-, di-, and trimethyllysines by lysine specific demethylase 1 (LSD1)⁸ and by specific Jumonji C (JmjC) domain-containing demethylases.^{8–12} To date, 17 lysine residues and seven arginine residues on histone proteins have been shown to undergo methylation^{12–16} and lysine methylation on histones can signal transcriptional activation or repression, depending on the specific lysine residue involved.^{17–19}

A key transcription-activating chromatin mark found associated with promoters of active genes is histone 3 dimethyllysine 4 (H3K4).^{20,21} The flavin adenine dinucleotide

Received: February 28, 2012

Published: August 9, 2012




Figure 1. Structures of previously discovered LSD1 inhibitors **1c** and **2d**, the monoamine oxidase inhibitors tranylcypromine **3** and pargyline **4**, and virtual screening hits **5–7**.

(FAD)-dependent amine oxidase LSD1, also known as BHC110 and KDM1,^{8,22} catalyzes the oxidative demethylation of histone 3 methyllysine 4 (H3K4me1) and histone 3 dimethyllysine 4 (H3K4me2), leading to transcriptional repression.⁸ Aberrant demethylation of H3K4me1 and H3K4me2 is known to prevent expression of tumor suppressor genes important in human cancer.²³ Thus, LSD1 and other histone demethylases have emerged as important new targets for the development of specific inhibitors as a new class of antitumor drugs.²⁴

To date, only a few small molecule inhibitors of LSD1 have been identified. The classical monoamine oxidase (MAO) inhibitors phenelzine and tranylcypromine inhibit the recombinant LSD1/CoRest complex and increase global levels of H3K4me2.^{22,25} Other recently described synthetic demethylase inhibitors include peptidic substrate mimics featuring modified lysine residues²⁶ and *trans*-2-arylcyclopropylamine analogues.^{27–29} All of the above are based either on the peptide substrate, making them unlikely candidates for drug development, or on a tranylcypromine scaffold. Among the most effective LSD1 inhibitors is the tranylcypromine-based inhibitor (1*S*,2*R*)-NCL-1 (IC₅₀ 1.6 μ M),^{30,31} and the (bis)-3,3-(diphenyl)propylbiguanide known as **2d**.^{32,33} A comprehensive review of inhibitors of lysine demethylases has recently been published.³⁴

We previously reported the synthesis of a novel series of (bis)guanidines and (bis)biguanides³⁵ that act as potent inhibitors of LSD1.²³ The two most potent LSD1 inhibitors, **1c** and **2d** (Figure 1), produced significant global increases in both H3K4me1 and H3K4me2 in HCT116 colon tumor cells *in vitro* and promoted the re-expression of multiple, aberrantly silenced genes important in the development of colon cancer, including members of the secreted frizzles-related proteins (SFRPs) and the GATA family of transcription factors. Compound **2d** has also been shown to produce a synergistic effect on tumor growth when combined with 5-azacytidine in nude mice bearing HCT116 human colon carcinoma xenografts.³³ These studies confirm that the use of histone


demethylase inhibitors in combination with a DNA methyltransferase inhibitor represents a highly promising and novel approach to cancer chemotherapy.

Because of the promising antitumor effects of **1c** and **2d**, we sought to find additional lead compounds for use as epigenetic modulators. Other groups have already pursued novel analogues related to the known monoamine oxidase inhibitors tranylcypromine **3** and pargyline **4** (Figure 1), however, we were interested in finding previously unknown scaffolds for use in LSD1 inhibitor design. Thus a virtual screen strategy was undertaken to examine the Maybridge Hitfinder 5 compound library, with the goal of identifying potential lead compounds. The crystal structure of LSD1 (Protein Data Bank 2V1D) was prepared for the virtual screen using PrepWizard, and SiteMap was then used to assess the “druggability” of the LSD1 histone-binding pocket and to map the active site. The active site features a hydrophilic pocket near the FAD cofactor, which appears to be the binding area for H3K4me2. Notably, the active site also contains a large hydrophobic pocket that could serve as a target for the structure-based design of inhibitor molecules. For the virtual screen, compounds in the Maybridge database were converted from 2D to 3D, and the lowest energy conformers were determined. These conformers were then docked in the LSD1 active site using Glide. A total of 10 hits were identified, each of which had a GlideScore lower than -7.5 kcal/mol. Each of the identified molecules contained a hydrophilic moiety that appeared to be situated near the FAD cofactor and a hydrophobic substituent that was bound in the hydrophobic pocket (data not shown). We examined these hits and selected three that seemed amenable to structural optimization, compounds **5**, **6**, and **7**, for our initial studies (Figure 1).


CHEMISTRY

Compounds **5–7** and analogues **8–33** could be readily synthesized using the routes described in Schemes 1–3. As was mentioned above, compounds **5–7** were among the virtual hits identified from the Maybridge Hitfinder 5 database, as was


Scheme 1



Scheme 2



Scheme 3



compound **12**, while the remaining analogues were largely unreported. The synthesis of carbamimidothioates **5**, **8**, and **9** could be completed in a single step, as shown in Scheme 1. The appropriate bromoalkylphthalimide **34a**, **34b**, or **34c** was treated with thiourea **35**³⁶ to afford the desired products **5**, **8**, and **9**, respectively, in 62–79% yield. In each case, the product precipitated from the reaction mixture as a white amorphous solid.

Compounds **6**, **10**, and **11** were also accessible in a single step using an adaptation of a previously published procedure,³⁷ as shown in Scheme 2. Treatment of 1,3-dinitro-2-chloro-5-(trifluoromethyl)benzene **35** with the appropriate diamine **36a–c** in the presence of triethylamine at 10 °C afforded the desired target molecules **6**, **10**, and **11** in 68–87% yield.

The remaining target molecules **7** and **12–33** were synthesized as outlined in Scheme 3. Thus substituted anilines **37–59** (see Table 1 for identities of R_1 , R_2 , and R_3) were treated with cyanoacetic acid in the presence of phosphorus pentachloride in dichloromethane,³⁸ resulting in the formation of the corresponding amides **60–82**. Yields for this transformation were largely between 85 and 95%, although in a few cases they were as low as 52%. These amides in turn were reacted with hydroxylamine and sodium bicarbonate in dichloromethane³⁹ to yield the desired amidoximes **7** and **12–33**. In this step, yields varied widely between 23 and 78%.

■ BIOLOGICAL EVALUATION

For synthetic histone demethylase inhibitors to be effective at the cellular level, any observed decreases in cellular LSD1 activity should be accompanied by an increase in global H3K4me1 and H3K4me2 content. The fortuitous decision to measure methylation changes prior to evaluating the analogues as LSD1 inhibitors was made based on our preliminary findings that suggested that fluorinated amidoximes such as **14** and **15**



produced significant changes in H3K4me2 levels in the Calu-6 human lung adenocarcinoma cell line. Thus, the ability of compounds **5–33** to produce increases in global H3K4me2 levels at both 24 and 48 h was measured as previously described.⁸ Although indicative of changes in gene transcription, increases in H3K4 methylation levels measured at 24 h are determined when cells are in log phase growth. Increases in H3K4 methylation at 48 h give a more realistic picture of changes in gene transcription because they are measured when cells are nearing confluence. Thus, only the results of these studies at 48 h are shown in Table 1, while H3K4me2 levels at 24 h appear in the Supporting Information (Table S1). Increases in H3K4me1 and H3K4me2 levels promoted by carbamimidothioates **5**, **8**, and **9** and the 2,5-dinitro-4-(trifluoromethyl)aniline derivatives **6**, **10**, and **11** were unremarkable at both 24 and 48 h. Among the fluorinated amidoximes **12–18**, compounds **16** and **17** promoted 21.4- and 12.4-fold increases at 48 h, respectively. Compounds **14** and **15** produced a 7.1- and 7.0-fold increase in H3K4me2 levels at 24 h, respectively, but this effect was not observed at 48 h. Compounds **12**, **13**, and **18** had no effect on H3K4me2 at this time point. Compound **17**, which featured a 2-fluoro substituent, produced a significant increase in H3K4me2 levels (12.4-fold) and was easier to access synthetically, and as such a series of 2-substituted aromatic amidoximes **19–33** was synthesized. Among these analogues, changes in the levels of H3K4me2 at 24 h ranged between 2.1-fold and 7658.7-fold, with the exception of compounds **19–21**, which had no significant effect at 24 h. At the 48 h time point, significant increases in H3K4me2 levels between 2.1- and 49-fold were observed, with the exception of compounds **19**, **20**, and **25**, which did not promote increases at the 48 h time point.



The ability of the target amidoximes **5–33** to inhibit LSD1 was determined in an assay procedure utilizing the recombinant

Table 1. Inhibition of Purified Recombinant LSD1 Following Treatment with 10 μM 3–33, and Fold Increase in Global H3K4me2 Levels in Calu-6 Human Lung Adenocarcinoma Cells Following Treatment with Carbamimidothioates 5, 8, and 9, Aromatic Amines 6, 10, and 11, and amidoximes 7 and 12–33 at 10 μM ^a

Structure	Compound	% inhibition of LSD1 at 10 μM	H3K4me2 Fold Increase (48 h)
	2d	82.9	5.1
	3	18.4	ND
	4	68.8	1.29
	5	24.0	1.94
	8	31.8	1.16
	9	17.3	1.16
	6	0.1	1.1
	10	5.5	1.1
	11	13.4	0.8
	7	31.7	0.62
	12	10.4	1.6
	13	0	7.1
	14	0	0.2
	15	25.3	1.2
	16	0	21.4
	17	5.6	12.44
	18	0	0.6
	19	15.4	1.4
	20	2.0	0.4
	21	0	6.2
	22	30.1	3.7
	23	8.6	2.1
	24	0	5.4
	25	0	0.8
	26	0	7.7
	27	10.4	13.4
	28	4.8	3.1
	29	0	13.1

Table 1. continued

Structure	Compound	% inhibition of LSD1 at 10 μ M	H3K4me2 Fold Increase (48 h)
	30	0	49.0
	31	0.2	6.7

Structure	Compound	% inhibition of LSD1 at 10 μ M	H3K4me2 Fold Increase (48 h)
	32	2.1	11.5
	33	16.6	3.1

^aEach data point is the average of three determinations that in each case differed by less than 5%. ND = not determined.




Figure 2. Fold increase in the expression of SFRP2 in Calu-6 anaplastic epithelial lung carcinoma cells. Cells were treated with either 1 mM aminoguanidine (AG), 5 μ M PN11144, 5 μ M 2d, or 10 μ M of the indicated test compound for 24 or 48 h. Each data point is the average of three determinations that in no case differed by more than 5%.

human enzyme. Expression and purification of LSD1 were conducted as previously reported.^{8,23} Enzymatic activity of LSD1 in the presence of target compounds was determined using luminol-dependent chemiluminescence to measure the production of H₂O₂, as previously described.^{23,40} The results of these experiments are summarized in Table 1. Compound 2d inhibited purified recombinant LSD1 by 82.9% at 10 μ M and initiated a 5-fold increase in cellular H3K4me2 levels in the Calu-6 cell model system, as previously reported.^{32,41} By contrast, the monoamine oxidase inhibitors tranylcypromine 3 and pargyline 4 inhibited the enzyme by 18.4 and 68.8% at 10 μ M, respectively. Carbamimidothioates 5, 8, and 9 were modest inhibitors of LSD1, producing 24.0, 31.8, and 17.3% inhibition at 10 μ M, but this inhibition did not correlate with an increase in H3K4me2 levels, as described above. The aminoalkylaniline derivatives 6, 10, and 11 were essentially inactive as inhibitors of recombinant LSD1 and also had no effect on lysine methylation in the Calu-6 cell line. Surprisingly, despite

promoting dramatic increases in cellular H3K4me2 levels at either 24 or 48 h, compounds 14–17, 23–27, 29, 31, and 33 were poor to modest inhibitors of LSD1. The most effective amidoxime inhibitor, 22, exhibited a 30.1% inhibition of the enzyme at 10 μ M and an IC₅₀ value of 16.8 μ M, which correlated with an 837.5-fold increase in H3K4me2 levels at 24 h. The parent compound 7 was a slightly better inhibitor (IC₅₀ 15.6 μ M), but remarkably, it did not produce any significant changes in H3K4 methylation. It is well established that the specificity of LSD1 for H3K4 demethylation is observed when the enzyme is bound to the CoREST.^{42,43} Thus one possible interpretation of the lack of correlation between LSD1 inhibition and increase in methylation is that the recombinant LSD1 used in the inhibition assay is not bound to the CoREST, a functional corepressor required for gene expression.⁴⁴ It is possible that amidoximes related to 22 are poor inhibitors of uncomplexed recombinant LSD1 *in vitro* but are more effective inhibitors of the LSD1/CoREST complex in cultured Calu-6




Figure 3. Fold increase in the expression of HCAD Calu-6 anaplastic epithelial lung carcinoma cells. Cells were treated with either 1 mM aminoguanidine (AG), 5 μ M PN11144, 5 μ M 2d, or 10 μ M of the indicated test compound for 24 or 48 h. Each data point is the average of three determinations that in no case differed by more than 5%.




Figure 4. Fold increase in the expression of GATA4 in Calu-6 anaplastic epithelial lung carcinoma cells. Cells were treated with either 1 mM aminoguanidine (AG), 5 μ M PN11144, 5 μ M 2d, or 10 μ M of the indicated test compound for 24 or 48 h. Each data point is the average of three determinations that in no case differed by more than 5%.

cells, a hypothesis that is supported by the molecular modeling studies described below.

The compounds that produced the most dramatic increases in global H3K4me2 levels, **22–27**, **29**, and **31**, were next examined for their ability to promote the re-expression of aberrantly silenced tumor suppressor genes in the Calu-6 cell line. The soluble modulator of Wnt signaling secreted frizzled-related protein 2 (SFRP2),⁴⁵ the membrane-bound mediator of calcium-dependent cell–cell adhesion H-cadherin (HCAD, CDH13),⁴⁶ and the zinc-finger transcription factor GATA4⁴⁷ were chosen because they are known to be under expressed in human lung cancer and because their silencing is thought to play a role in tumorigenesis.⁴¹ Cells were treated for 24 or 48 h with a 5 μM concentration of **2d** or the polyamine analogue PN11144⁴⁸ or a 10 μM concentration of each amidoxime analogue, after which the levels of SFRP2, HCAD, and GATA4 were determined by quantitative PCR (qPCR).^{32,41} In the case of each re-expressed protein, a fold increase of ≥ 1.5 was considered significant. Four of the amidoxime analogues evaluated, **25**, **27**, **29**, and **31** produced increases in SFRP2 levels (**25**, 2.29-fold at 24 h, 1.45-fold at 48 h; **27**, 1.69-fold at 24 h; **29**, 1.55-fold at 48 h; **31**, 1.89-fold at both 24 and 48 h, Figure 2). However, none of these increases were of the same magnitude as the increases promoted by the positive control **2d**. Aminoguanidine at 1 mM (AG) and the polyamine analogue PG11144⁴⁸ had no effect on SFRP2 levels. In the case of HCAD (Figure 3), significant increases were observed with 10 μM **23** (1.6-fold at 48 h), **26** (1.6-fold at 48 h), **27** (1.58 fold at 48 h), **29** (1.8-fold at 48 h), and **31** (2.15-fold at 48 h). By contrast, **2d** increased HCAD expression by 1.62-fold at 24 h and 3.83-fold at 48 h. PG11144 also had an effect at 10 μM (1.47-fold) at 24 h. The most dramatic effects were observed in the case of the transcription factor GATA4 (Figure 4), where increased expression was observed following treatment with **23** (1.69-fold at 48 h), **26** (1.57-fold at 24 h, 1.77-fold at 48 h), **27** (2.06-fold at 24 h), **29** (1.66-fold at 24 h), and **31** (4.22-fold at 48 h). These effects were comparable to **2d** (2.07-fold at 24 h, 1.94-fold at 48 h) for **27** (24 h) and **31**, which had twice the effect of **2d** at 48 h.

Importantly, the magnitudes of the observed increases in H3K4 methylation induced by amidoximes **22–27**, **29**, and **31** do not correlate well with the re-expression of the aberrantly silenced gene products chosen for this study (SFRP2, HCAD, and GATA4). However, the dramatic nature of the observed increases in H3K4me2 methylation suggest that significant changes in cellular gene expression must be taking place. As such, we are currently undertaking a DNA microarray strategy to determine which genes are affected in tumor cells following treatment with amidoximes **22–27**, **29**, and **31**.

IN SILICO ANALYSIS

To provide a rationale for the observed biological activity of the amidoxime inhibitors, we performed an in silico docking experiment using the GOLD software package.⁴⁹ At present, there are 27 published X-ray structures of LSD1, including those crystallized with and without the CoREST complex and with and without a bound ligand. For our purposes, we selected PDB structure 2V1D because it featured the necessary components (the LSD1 binding pocket, a cocrystallized inhibitor as ligand, free FAD, and the associated CoREST complex),⁵⁰ and compound **22**, which was the best LSD1 inhibitor in vitro (Table 1). The inhibitor in the 2 V1D complex is a 21-mer pLys4Met H3 peptide in which a

methionine takes the place of the lysine corresponding to H3K4.⁵⁰ The pLys4Met H3 peptide exhibited a 30-fold greater binding affinity ($K_i = 0.05 \mu\text{M}$) as compared to the wild-type peptide ($K_i = 1.8 \mu\text{M}$). Because the LSD1 binding pocket and the 21-mer cocrystal peptide ligand are relatively large, we included only the residues that lie within 6 Å around the ligand in our analysis. The pLys4Met H3 ligand was removed, and the energy-minimized amidoxime **22** was substituted and docked in the binding site of LSD1/CoREST (see the Experimental Section). The resulting poses were scored using ChemScore.⁴⁹

Visualization of the lowest energy binding mode of **22** in the LSD1/CoREST binding site revealed that **22** binds to the same region as that occupied by the pThr³ and pMet⁴ of the pLys4Met H3 peptide, as shown in Figure 5. This result




Figure 5. Graphic representation of binding mode of amidoxime **22** in the LSD1-CoREST complex active site. (A) Distance between the amidoxime functionality of **22** and N-5 of the flavin ring of FAD; distance between the MET residue of the Forneris inhibitor and N-5 of the flavin ring of FAD. (B) Hydrogen bonding distances between **22** and amino acid residues THR 335, ALA 539, and TYR 761.

supports the hypothesis that **22** and related amidoximes occupy the active site of LSD1. The distance between the enolic hydroxyl group of **22** and N5 of the FAD is about 6.3 Å, whereas the distance between the sulfur of pMet⁴ and N5 of the FAD is about 4.9 Å, demonstrating that the amidoxime moiety of **22** lies in proximity to the FAD binding domain. The phenyl group in **22** is situated in a hydrophobic cavity surrounded by residues Phe 560, Tyr 807, and His 812. Interestingly, this is the region that is occupied by the side chain of the p3 Thr of pLys4Met H3 peptide. As shown in Figure 5, the phenolic hydroxyl group of the amidoxime forms a hydrogen bond with the side chain hydroxyl group of Thr 335, while the primary amine group of the amidoxime moiety forms hydrogen bond with the backbone carbonyl of Ala 539. This interaction is




Figure 6. Results of in silico docking of amidoxime **22** in the active site of the LSD1/CoREST complex. The FAD cofactor is shown in red, and distances are in angstroms.

analogous to the hydrogen bond formed between the amide nitrogen of pAla¹ in the pLys4Met H3 ligand and the backbone carbonyl of Ala339, underscoring the importance of this interaction. Finally, the enolic hydroxyl of the amidoxime forms a hydrogen bond with both the backbone carbonyl of Ala 539 and the 4-hydroxyl group of Tyr 761. These docking results suggest that **22** binds to the LSD1/CoREST active site in exactly the same region as both H3K4 of the histone tail and pMet⁴ of the pLys4Met H3 peptide. A combination of both hydrogen bonding and hydrophobic interactions stabilize the LSD1/CoREST complex with **22** (Figure 6), positioning it directly in front of the FAD cofactor and blocking the access of the substrate to the FAD. A similar docking experiment involving **22** and native LSD1 lacking the CoREST cofactor (PDB index 2H94) revealed that these specific interactions between **22** and the amino acids Thr 335, Ala 539, and Tyr 761 are not present (Supporting Information, Figure S1). In this model, the amidoxime moiety of **22** forms a hydrogen bond with N5 of the flavin ring, but no other electrostatic associations could be detected. Although the models shown in Figures 6 and Supporting Information S1 are preliminary, they support the contention that **22** acts as an inhibitor of LSD1 only when the CoREST corepressor is present. These data could also explain the observation that large increases in H3K4me2 levels following treatment with **22** and its homologues do not correlate with inhibition of LSD1 in the assay, which does not contain CoREST. Importantly, the in silico model shown in Figure 6 suggest modifications to **22** which could lead to more potent analogues.

DISCUSSION

Our virtual screening strategy resulted in the identification of 10 potential LSD1 inhibitors that have desirable drug-like properties and can be readily synthesized. Many of the inhibitors of LSD1 described in the recent literature are based either on the tranylcypramine scaffold or are oligopeptides that are unlikely to be used as therapeutic agents. More recently, a series of small molecules was described that inhibit LSD1, enhance H3K4 methylation, and promote the re-

expression of aberrantly silenced tumor suppressor genes. These analogues were also shown to selectively inhibit the growth of tumor cells with pluripotent stem cell properties.⁵¹ However, these analogues are structurally related to the (bis)guanidine, (bis)biguanide, (bis)urea, and (bis)thiourea analogues previously described in our laboratories,^{32,41,52} which produce similar cellular effects in nonpluripotent tumor cell lines and exhibit in vivo activity.³³ Compared to the known LSD1 inhibitors described above, compound **22** and its homologues possess more favorable drug-like properties⁵³ (CLogP 0.37, MW 208.21, 5 H-bond acceptors, 4 H-bond donors) and can be readily synthesized in two steps. Amidoximes **22–27**, **29**, and **31** produce dramatic increases in global H3K4me2 levels and also promote the re-expression of aberrantly silenced tumor suppressor genes in the Calu-6 cell line. Thus, these compounds, and in particular **22**, can be considered lead compounds within a new structural class of histone demethylase inhibitors. We have initiated lead optimization studies and will report the data from these studies in a future manuscript. Additional studies are being performed to determine which aberrantly silenced genes are reactivated secondary to the dramatic increases in H3K4 methylation observed for amidoximes **22–27**, **29**, and **31**. In addition, amidoximes **22–27**, **29**, and **31** are being evaluated in other tumor cell lines, alone and in combination with the DNA methyltransferase inhibitor 5-azacytidine as well as in a murine xenograft model.

EXPERIMENTAL SECTION

All reagents and dry solvents were purchased from Aldrich Chemical Co. (Milwaukee, WI), Sigma Chemical Co. (St. Louis, MO), or Acros Chemical (Chicago, IL) and were used without further purification except as noted below. Pyridine was dried by passing it through an aluminum oxide column and then stored over KOH. Triethylamine was distilled from potassium hydroxide and stored in a nitrogen atmosphere. Methanol was distilled from magnesium and iodine under a nitrogen atmosphere and stored over molecular sieves. Methylene chloride was distilled from phosphorus pentoxide, and chloroform was distilled from calcium sulfate. Tetrahydrofuran was purified by distillation from sodium and benzophenone. Dimethyl formamide

was dried by distillation from anhydrous calcium sulfate and was stored under nitrogen. Preparative scale chromatographic procedures were carried out using E. Merck silica gel 60, 230–440 mesh. Thin layer chromatography was conducted on Merck precoated silica gel 60 F-254. Ion exchange chromatography was conducted on Dowex 1 × 8–200 anion exchange resin. Compounds **41a–c**^{35,54} were synthesized as previously described.

All ¹H and ¹³C NMR spectra were recorded on a Varian Mercury 400 MHz spectrometer, and all chemical shifts are reported as δ values referenced to TMS or DSS. In all cases, ¹H NMR, ¹³C NMR, and MS spectra were consistent with assigned structures. Mass spectra were recorded by LC/MS on a Waters autopurification liquid chromatograph with a 3100 mass spectrometer detector. Prior to biological testing procedures, target molecules **5–33** were determined to be >95% pure by UPLC chromatography (95% H₂O/5% acetonitrile to 20% H₂O/80% acetonitrile over 10 min) using a Waters Acquity H-series ultrahigh-performance liquid chromatograph fitted with a C18 reversed-phase column (Acquity UPLC BEH C18 1.7 μ M, 2.1 mm × 50 mm).

Synthetic H3K4me2 peptides were purchased from Millipore (Billerica, MA). Calu-6 cells were maintained in RPMI medium, both supplemented with 10% fetal bovine serum (Gemini Bio-Products, Woodland, CA) and grown at 37 °C in 5% CO₂ atmosphere.

General Procedure for Preparation Carbamimidothioate **5, **8**, and **9**.**³⁶ *N*-(Phthalimido)ethyl Carbamimidothioate Hydrochloride **5**. A 3.0 g (11.6 mmol) portion of *N*-(2-bromoethyl)phthalimide **34a** and 1.77 g (12.1 mmol, 2.0 equiv) of thiourea was dissolved in 10 mL of anhydrous ethanol, and the mixture was allowed to reflux overnight. The reaction mixture was allowed to cool until a white crystalline precipitate formed, and the solid was collected by filtration, washed with acetone and ether, and dried. Recrystallization from 1.0 M HCl/ethanol then afforded 2.05 g (62%) of pure **5** as a white crystalline solid. Melting point 380–381 °C; UPLC retention time 3.47 min. ¹H NMR (CD₃OD) δ 3.54 (t, *J* = 6.4 Hz, 2H), 4.05 (t, *J* = 6.4 Hz, 2H), 7.90 (m, 4H).

N-(Phthalimido)propyl carbamimidothioate Hydrochloride **8**. Compound **8** was prepared from 3.0 g (11.2 mmol) of *N*-(3-bromopropyl)phthalimide **34b** and 1.70 g (22.4 mmol, 2.0 equiv) of thiourea in 68% yield exactly as described for the preparation of compound **5**. Melting point 362–363 °C; UPLC retention time 4.45 min. ¹H NMR (CD₃OD) δ 2.11 (quint, *J* = 6.8 Hz, 2H), 3.22 (t, 3.22, *J* = 6.8 Hz, 2H), 3.85 (t, *J* = 6.8 Hz, 2H), 7.87 (m, 4H).

N-(Phthalimido)butyl carbamimidothioate Hydrochloride **9**. Compound **9** was prepared from 1.5 g (5.2 mmol) of *N*-(4-bromobutyl)phthalimide **34c** and 0.79 g (10.4 mmol, 2.0 equiv) of thiourea in 79% yield exactly as described for the preparation of compound **5**. Melting point 358–359 °C; UPLC retention time 5.32 min. ¹H NMR (CD₃OD) δ 1.82 (m, 4H), 3.22 (t, *J* = 7.3 Hz, 2H), 3.75 (t, *J* = 6.7 Hz, 2H), 7.86 (m, 4H).

General Procedure for the Preparation of Compounds **6, **10**, and **11**.**³⁷ *N*-(2,6-Dinitro-4-[(trifluoromethyl)phenyl]ethane-1,2-diamine Hydrochloride **6**. A solution of ethylene diamine **36a** (6.0 g, 100 mmol, 6.7 mL, 2.0 equiv) and triethylamine (0.51 g, 0.70 mL, 5.0 mmol) in 40 mL of benzene was cooled to 10 °C, and a solution of 4-chloro-3,5-dinitrobenzotrifluoride **35** (1.36 g, 5.00 mmol) in 40 mL of benzene was added dropwise over 2 h. The reaction was stirred overnight and concentrated in vacuo to yield an orange liquid. This liquid was dissolved in 200 mL of ethyl acetate, and the organic layer was washed with two 25 mL portions of water and then 25 mL of saturated aqueous NaCl. The ethyl acetate solution was dried over anhydrous MgSO₄, filtered, and concentrated, and the crude mixture was purified by column chromatography on silica gel (with a gradient of 1:1 hexanes:AcOEt to AcOEt to 3:1 AcOEt:MeOH). Fractions containing the desired product (*R*_f = 0.39) were pooled and concentrated to give an orange solid, which was dissolved in ethyl acetate. A 1.0 M solution of HCl in ethyl acetate was added until no more product dropped out of solution. The product was filtered and washed with ethyl acetate to afford pure **6** as the yellow solid dihydrochloride salt (1.55 g, 84.7% yield). Melting point 324–326 °C (dec.); UPLC retention time 6.22 min. ¹H NMR (400 MHz, CDCl₃) δ

9.45 (bs, 1H), 8.41 (s, 2H), 3.10–2.95 (m, 4H), 1.27 (bs, 2H). ¹⁹F NMR (376 MHz, CDCl₃) δ –62.36 (s, 3F).

N-(2,6-Dinitro-4-[(trifluoromethyl)phenyl]propane-1,2-diamine Hydrochloride **10**. Compound **10** was prepared from 7.41 g (100.0 mmol) of 1,3-propanediamine **36b** and 0.79 g of 4-chloro-3,5-dinitrobenzotrifluoride **35** (5.00 mmol) in 87% yield exactly as described for the preparation of compound **6**. Melting point 380–381 °C (dec.); UPLC retention time 6.69 min. ¹H NMR (400 MHz, CDCl₃) δ 9.52 (bs, 1H), 8.39 (s, 2H), 3.14 (s, 2H), 2.94 (t, *J* = 6.0 Hz, 2H), 1.78 (quint, *J* = 6.0 Hz, 2H), 1.33 (bs, 2H). ¹⁹F NMR (376 MHz, CDCl₃) δ –62.36 (s, 3F).

N-(2,6-Dinitro-4-[(trifluoromethyl)phenyl]butane-1,2-diamine Hydrochloride **11**. Compound **11** was prepared from 8.81 g (100.0 mmol) of 1,4-butanediamine **36c** and 0.79 g of 4-chloro-3,5-dinitrobenzotrifluoride **35** (5.00 mmol) in 42% yield exactly as described for the preparation of compound **6**. Melting point 374–376 °C (dec.); UPLC retention time 7.05 min. ¹H NMR (400 MHz, D₂O) δ 8.48 (s, 2H), 2.94 (t, *J* = 6.4 Hz, 2H), 2.84 (t, *J* = 7.2 Hz, 2H), 1.70–1.50 (m, 4H). ¹⁹F NMR (376 MHz, D₂O) δ –62.51 (s, 3F).

General Procedure for the Preparation of Cyano-*N*-phenylacetamides **60–82.**³⁸ *N*-Cyano-*N*-phenylacetamide **60**. A 0.96 g portion (11.1 mmol) of cyanoacetic acid was added to a mixture of PCl₅ (2.35 g, 11.1 mmol) and 200 mL of dichloromethane, and the mixture refluxed for 30 min. After cooling, 1.03 g of aniline (11.1 mmol) was added and the solution was refluxed for 2 h. The solution was then concentrated, H₂O was added, and the solid was collected and washed with NaHCO₃ solution and H₂O and dried. The intermediate **60** was isolated in 92% yield and was of sufficient purity to use in the subsequent reaction without further purification. ¹H NMR (400 MHz, acetone-*d*₆) δ 9.58 (s, 1H), 7.62 (d, *J* = 8.4 Hz, 2H), 7.33 (t, *J* = 8.0 Hz, 2H), 7.11 (t, *J* = 7.2 Hz, 1H), 3.82 (s, 2H).

N-(2,3,4-trifluorophenyl)acetamide **61**. Compound **61** was synthesized in 90% yield exactly as described for the preparation of compound **60**; white solid. ¹H NMR (400 MHz, acetone-*d*₆) δ 9.60 (s, 1H), 7.89–7.83 (m, 1H), 7.29–7.14 (m, 1H), 3.97 (s, 2H). ¹⁹F NMR (376 MHz, acetone-*d*₆) δ –141.75 (m, 1F), –147.85 (m, 1F), –162.75 (m, 1F).

N-(2,4-difluorophenyl)acetamide **62**. Compound **62** was synthesized in 76% yield exactly as described for the preparation of compound **60**; white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.14 (s, 1H), 7.84–7.77 (m, 1H), 7.37–7.32 (m, 1H), 7.12–7.05 (m, 1H), 3.96 (s, 2H). ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ –114.33 (m, 1F), –119.95 (s, 1F).

N-(2,3-difluorophenyl)acetamide **63**. Compound **63** was synthesized in 83% yield exactly as described for the preparation of compound **60**; yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.33 (s, 1H), 7.66 (s, 1H), 7.24–7.14 (m, 2H), 3.99 (s, 2H). ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ –138.69 (m, 1F), –149.64 (m, 1F).

N-(4-fluorophenyl)acetamide **64**. Compound **64** was synthesized in 83% yield exactly as described for the preparation of compound **60**; white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.34 (s, 1H), 7.55–7.53 (m, 2H), 7.20–7.13 (m, 2H), 3.88 (s, 2H). ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ –118.87 (s, 1F).

N-(3,4-difluorophenyl)acetamide **65**. Compound **65** was synthesized in 94% yield exactly as described for the preparation of compound **60**; white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.52 (s, 1H), 7.76–7.64 (m, 1H), 7.45–7.30 (m, 1H), 7.25–7.20 (m, 1H), 3.89 (s, 2H). ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ –137.20 (m, 1F), –144.36 (m, 1F).

N-(2-fluorophenyl)acetamide **66**. Compound **66** was synthesized in 85% yield exactly as described for the preparation of compound **60**; white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.15 (s, 1H), 7.87 (t, *J* = 8.8 Hz, 1H), 7.35–7.13 (m, 3H), 3.99 (s, 2H). ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ –126.08 (m, 1F).

N-(3-fluorophenyl)acetamide **67**. Compound **67** was synthesized in 68% yield exactly as described for the preparation of compound **60**; white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.53 (s, 1H), 7.52 (dt, *J* = 11.6 Hz, 2.0 Hz, 1H), 7.41–7.34 (m, 1H), 7.28–7.23 (m, 1H), 6.93 (td, *J* = 6.0 Hz, 2.4 Hz, 1H), 3.93 (s, 2H). ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ –112.15 (m, 1F).

2-Cyano-N-[2-(methoxy)phenyl]acetamide 68. Compound **68** was synthesized in 94% yield exactly as described for the preparation of compound **60**; white solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.34 (bs, 1H), 8.25 (dd, $J = 8.0, 2.0$ Hz, 1H), 7.12 (td, $J = 8.0, 1.6$ Hz, 1H), 6.97 (dt, $J = 8.0, 1.2$ Hz, 1H), 6.91 (dd, $J = 8.0, 1.2$ Hz, 1H), 3.91 (s, 3H), 3.56 (s, 2H).

2-Cyano-N-[2-(nitro)phenyl]acetamide 69. Compound **69** was synthesized in quantitative yield exactly as described for the preparation of compound **60**; tan solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 10.92 (bs, 1H), 8.68 (dd, $J = 8.4, 1.2$ Hz, 1H), 8.27 (dd, $J = 8.4, 1.6$ Hz, 1H), 7.71 (dt, $J = 8.4, 1.6$ Hz, 1H), 7.30 (dt, $J = 8.0, 1.2$ Hz, 1H), 3.67 (s, 2H).

2-Cyano-N-[2-(methyl)phenyl]acetamide 70. Compound **70** was synthesized in 94% yield exactly as described for the preparation of compound **60**; white solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.73 (bs, 1H), 7.66 (d, $J = 7.6$ Hz, 1H), 7.26–7.11 (m, 3H), 3.56 (s, 2H), 2.28 (s, 3H).

2-Cyano-N-[2-(hydroxyl)phenyl]acetamide 71. Compound **71** was synthesized in 52% yield exactly as described for the preparation of compound **60**; pale purple–white solid. $^1\text{H NMR}$ (400 MHz, acetone- d_6) δ 9.09 (bs, 1H), 7.94 (dd, $J = 8.0, 1.2$ Hz, 1H), 6.99 (dt, $J = 8.4, 1.2$ Hz, 1H), 6.92 (dd, $J = 8.0, 1.2$ Hz, 1H), 6.84 (dt, $J = 8.0, 1.2$ Hz, 1H), 3.98 (s, 2H). $^{13}\text{C NMR}$ (100 MHz, acetone- d_6) δ 162.1, 148.1, 126.9, 126.1, 122.4, 120.6, 116.6, 115.8, 27.1.

2-Cyano-N-[2-(mercapto)phenyl]acetamide 72. Compound **72** was synthesized in 66% yield exactly as described for the preparation of compound **60**, except that the material was further purified by dissolving the residue in dichloromethane and filtering through silica gel plug; light-yellow solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.04 (d, $J = 8.0$ Hz, 1H), 7.90 (d, $J = 8.0$ Hz, 1H), 7.53 (t, $J = 8.0$ Hz, 1H), 7.45 (t, $J = 8.0$ Hz, 1H), 4.24 (s, 2H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 158.4, 152.8, 135.5, 126.7, 126.0, 123.3, 121.8, 115.1, 23.2.

2-Cyano-N-[2-(ethyl)phenyl]acetamide 73. Compound **73** was synthesized in 81% yield exactly as described for the preparation of compound **60**; off-white solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.74 (bs, 1H), 7.68 (dd, $J = 7.6, 1.6$ Hz, 1H), 7.26–7.17 (m, 3H), 3.57 (s, 2H), 2.63 (q, $J = 7.6$ Hz, 2H), 1.26 (t, $J = 7.6$ Hz, 3H).

2-Cyano-N-[2-(isopropyl)phenyl]acetamide 74. Compound **74** was synthesized in quantitative yield exactly as described for the preparation of compound **60**, except that the oil was dissolved in 100 mL of ethyl acetate, and the organic layer was washed with 1.0 N sodium bicarbonate and saturated aqueous NaCl. Filtration and evaporation of the solvent then afforded pure **74** as an orange oil that solidified at RT. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.85 (bs, 1H), 7.52 (dd, $J = 7.6, 1.2$ Hz, 1H), 7.32 (dd, $J = 7.6, 1.2$ Hz, 1H), 7.29–7.17 (m, 2H), 3.54 (s, 2H), 3.02 (septet, $J = 6.8$ Hz, 1H), 1.24 (d, $J = 6.8$ Hz, 6H).

2-Cyano-N-[2-(phenyl)phenyl]acetamide 75. Compound **75** was synthesized in 97% yield exactly as described for the preparation of compound **60**; white solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.20 (d, $J = 8.4$ Hz, 1H), 7.79 (bs, 1H), 7.55–7.23 (m, 9H), 3.39 (s, 2H).

2-Cyano-N-[2-(ethoxy)phenyl]acetamide 76. Compound **76** was synthesized in 81% yield exactly as described for the preparation of compound **60**; white solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.52 (bs, 1H), 8.26 (d, $J = 8.0$ Hz, 1H), 7.10 (t, $J = 8.0$ Hz, 1H), 6.97 (t, $J = 7.6$ Hz, 1H), 6.90 (d, $J = 8.0$ Hz, 1H), 4.13 (q, $J = 6.8$ Hz, 2H), 3.57 (s, 2H), 1.49 (t, $J = 6.8$ Hz, 3H).

2-Cyano-N-[2-(phenoxy)phenyl]acetamide 77. Compound **77** was synthesized in quantitative yield exactly as described for the preparation of compound **60**; light-yellow solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.32 (dd, $J = 8.0, 1.6$ Hz, 1H), 8.29 (bs, 1H), 7.41–7.34 (m, 2H), 7.20–7.01 (m, 5H), 6.87 (dd, $J = 8.0, 1.2$ Hz, 1H), 3.53 (s, 2H).

2-Cyano-N-[2-(trifluoromethyl)phenyl]acetamide 78. Compound **78** was synthesized in 89% yield exactly as described for the preparation of compound **60**; white solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.03 (d, $J = 8.4$ Hz, 1H), 8.00 (bs, 1H), 7.67 (d, $J = 7.6$ Hz, 1H), 7.61 (t, $J = 7.6$ Hz, 1H), 7.35 (t, $J = 7.6$ Hz, 1H), 3.61 (s, 2H). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ –60.98 (s).

2-Cyano-N-[2-(chloro)phenyl]acetamide 79. Compound **79** was synthesized in 90% yield exactly as described for the preparation of

compound **60**; off-white solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.25 (dd, $J = 8.0, 1.2$ Hz, 1H), 8.24 (bs, 1H), 7.41 (dd, $J = 8.0, 0.8$ Hz, 1H), 7.31 (td, $J = 8.0, 1.2$ Hz, 1H), 7.13 (td, $J = 7.6, 1.2$ Hz, 1H), 3.62 (s, 2H).

2-Cyano-N-[2-(bromo)phenyl]acetamide 80. Compound **80** was synthesized in 95% yield exactly as described for the preparation of compound **60**; white solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.24 (dd, $J = 8.0, 1.2$ Hz, 1H), 8.24 (bs, 1H), 7.58 (dd, $J = 8.0, 1.2$ Hz, 1H), 7.35 (td, $J = 8.0, 1.2$ Hz, 1H), 7.07 (td, $J = 7.6, 1.2$ Hz, 1H), 3.62 (s, 2H).

2-(2-Cyanoacetamido)benzamide 81. Compound **81** was synthesized in 97% yield exactly as described for the preparation of compound **60**; white solid. $^1\text{H NMR}$ (400 MHz, $\text{DMSO}-d_6$) δ 11.83 (bs, 1H), 8.32 (d, $J = 8.4$ Hz, 1H), 8.31 (s, 1H), 7.80 (dd, $J = 8.0, 1.2$ Hz, 1H), 7.78 (s, 1H), 7.52 (td, $J = 8.0, 1.2$ Hz, 1H), 7.18 (td, $J = 7.6, 1.2$ Hz, 1H), 4.07 (s, 2H).

Ethyl 2-(2-Cyanoacetamido)benzoate 82. Compound **82** was synthesized in 96% yield exactly as described for the preparation of compound **60**; white solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.75 (bs, 1H), 8.61 (d, $J = 8.0$ Hz, 1H), 8.09 (dd, $J = 8.0, 1.6$ Hz, 1H), 7.58 (td, $J = 8.0, 1.6$ Hz, 1H), 7.17 (td, $J = 7.6, 1.2$ Hz, 1H), 4.42 (q, $J = 7.2$ Hz, 2H), 3.61 (s, 2H), 1.42 (t, $J = 7.2$ Hz, 3H).

General Procedure for the Preparation of Amidoximes 7 and 12–33.³⁹ **3-Amino-3-(hydroxyimino)-N-phenylpropanamide 7.** A 0.9 g portion of $\text{NH}_2\text{OH}\cdot\text{HCl}$ (12.8 mmol) was added to a mixture of sodium carbonate (1.36 g, 12.8 mmol) in 5 mL of water, and the solution was diluted with 50 mL of MeOH. A 1.64 g portion (10.2 mmol) of compound **60** was then added, and the mixture refluxed for 2 h. The mixture was cooled, the solvent was removed in vacuo, and the resulting solid was mixed with hot 3:1 AcOEt:MeOH. The insoluble material was then removed by filtration of the hot mixture, and the filtrate was concentrated and purified by chromatography on silica gel (gradient of AcOEt \rightarrow 20:1 AcOEt:MeOH). Fractions containing the product were pooled and the solvent was removed, and the resulting solid was recrystallized from MeOH/EtOAc to afford 0.67 g (34%) of pure **7** as a white amorphous solid. An analytical sample was prepared by recrystallization from 1.0 M HCl/ethanol. Melting point 312–313 °C (dec.); UPLC retention time 2.29 min. $^1\text{H NMR}$ (400 MHz, acetone- d_6) δ 9.53 (s, 1H), 8.70 (s, 1H), 7.65–7.63 (m, 2H), 7.31–7.27 (m, 2H), 7.07–7.04 (m, 1H), 5.39 (s, 2H), 3.17 (s, 2H).

3-Amino-3-(hydroxyimino)-N-[2,3,4-(trifluoro)phenyl]propanamide 12. Compound **12** was synthesized from **61** in 26% yield exactly as described for the preparation of compound **7**; white crystals; melting point 310–312 °C (dec.); UPLC retention time 6.07 min. $^1\text{H NMR}$ (400 MHz, acetone- d_6) δ 9.72 (s, 1H), 8.79 (s, 1H), 7.99–7.92 (m, 1H), 7.19–7.12 (m, 1H), 5.45 (s, 2H), 3.28 (s, 2H). $^{19}\text{F NMR}$ (376 MHz, acetone- d_6) δ –143.11 (m, 1F), –148.97 (m, 1F), –163.25 (m, 1F).

3-Amino-3-(hydroxyimino)-N-[2,4-(difluoro)phenyl]propanamide 13. Compound **13** was synthesized from **62** in 59% yield exactly as described for the preparation of compound **7**; white solid; melting point 314–315 °C (dec.); UPLC retention time 2.36 min. $^1\text{H NMR}$ (400 MHz, $\text{DMSO}-d_6$) δ 9.83 (s, 1H), 9.06 (d, $J = 6.8$ Hz, 1H), 7.93–7.85 (m, 1H), 7.33–7.27 (m, 1H), 7.06–7.03 (m, 1H), 5.48 (s, 2H), 3.12 (d, $J = 0.64$ Hz, 2H). $^{19}\text{F NMR}$ (376 MHz, $\text{DMSO}-d_6$) δ –115.49 (d, 1F), –120.73 (bs, 1F).

3-Amino-3-(hydroxyimino)-N-[2,3-(difluoro)phenyl]propanamide 14. Compound **13** was synthesized from **63** in 43% yield exactly as described for the preparation of compound **7**; white solid; melting point 290–292 °C (dec.); UPLC retention time 2.67 min. $^1\text{H NMR}$ (400 MHz, $\text{DMSO}-d_6$) δ 10.01 (s, 1H), 9.05 (s, 1H), 7.75–7.72 (m, 1H), 7.19–7.09 (m, 2H), 5.48 (s, 2H), 3.14 (s, 2H). $^{19}\text{F NMR}$ (376 MHz, $\text{DMSO}-d_6$) δ –139.10 (m, 1F), –150.53 (m, 1F).

3-Amino-3-(hydroxyimino)-N-[4-(fluoro)phenyl]propanamide 15. Compound **15** was synthesized from **64** in 53% yield exactly as described for the preparation of compound **7**; white solid; melting point 299–300 °C (dec.); UPLC retention time 2.76 min. $^1\text{H NMR}$ (400 MHz, $\text{DMSO}-d_6$) δ 10.07 (s, 1H), 9.02 (s, 1H), 7.61–7.57 (m, 2H), 7.15–7.10 (m, 2H), 5.44 (bs, 2H), 3.03 (s, 2H). $^{19}\text{F NMR}$ (376 MHz, $\text{DMSO}-d_6$) δ –119.87 (m, 1F).

3-Amino-3-(hydroxyimino)-N-[3,4-(difluoro)phenyl]propanamide 16. Compound 16 was synthesized from 65 in 68% yield exactly as described for the preparation of compound 7; white solid; melting point 320–322 °C (dec.); UPLC retention time 3.87 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.23 (s, 1H), 9.12–9.04 (m, 1H), 7.81–7.76 (m, 1H), 7.40–7.34 (m, 1H), 7.33–7.28 (m, 1H), 5.47 (s, 2H), 3.06–3.01 (m, 2H). ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ –137.60 (m, 1F), –145.33 (s, 1F).

3-Amino-3-(hydroxyimino)-N-[2-(fluoro)phenyl]propanamide 17. Compound 17 was synthesized from 66 in 51% yield exactly as described for the preparation of compound 7; white solid; melting point 294–297 °C (dec.); UPLC retention time 1.95 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.79 (s, 1H), 9.05 (s, 1H), 7.97–7.88 (m, 1H), 7.25–7.05 (m, 3H), 5.48 (s, 1H), 3.13 (s, 2H). ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ –126.09 (m, 1F).

3-Amino-3-(hydroxyimino)-N-[3-(fluoro)phenyl]propanamide 18. Compound 18 was synthesized from 67 in 53% yield exactly as described for the preparation of compound 7; white solid; melting point 338–340 °C (dec.); UPLC retention time 3.32 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.23 (s, 1H), 9.04 (s, 1H), 7.58 (d, *J* = 13.2 Hz, 1H), 7.33–7.66 (m, 2H), 6.88–6.84 (m, 1H), 5.46 (s, 1H), 3.06 (s, 1H). ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ –112.45 (m, 1F).

3-Amino-3-(hydroxyimino)-N-[2-(methoxy)phenyl]propanamide 19. Compound 19 was synthesized from 68 in 67% yield exactly as described for the preparation of compound 7; white crystals; melting point 277–278 °C (dec.); UPLC retention time 2.94 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.41 (s, 1H), 9.13 (s, 1H), 8.08 (d, *J* = 8.0 Hz, 1H), 7.08–7.00 (m, 2H), 6.90 (dt, *J* = 8.0, 1.6 Hz, 1H), 5.60 (s, 2H), 3.83 (s, 3H), 3.14 (s, 2H).

3-Amino-3-(hydroxyimino)-N-[2-(nitro)phenyl]propanamide 20. Compound 20 was synthesized from 69 in 72% yield exactly as described for the preparation of compound 7; orange–yellow crystals; melting point 294–295 °C (dec.); UPLC retention time 2.09 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.51 (s, 1H), 9.14 (s, 1H), 8.08 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.91 (d, *J* = 8.0 Hz, 1H), 7.72 (dt, *J* = 8.0, 0.8 Hz, 1H), 7.36 (dt, *J* = 8.0, 0.8 Hz, 1H), 5.55 (s, 2H), 3.13 (s, 2H).

3-Amino-3-(hydroxyimino)-N-[2-(methyl)phenyl]propanamide 21. Compound 21 was synthesized from 70 in 78% yield exactly as described for the preparation of compound 7; white crystals; melting point 290–291 °C (dec.); UPLC retention time 2.55 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.44 (s, 1H), 9.09 (s, 1H), 7.51 (d, *J* = 7.6 Hz, 1H), 7.20 (d, *J* = 7.2 Hz, 1H), 7.15 (t, *J* = 7.6 Hz, 1H), 7.06 (t, *J* = 7.2 Hz, 1H), 5.53 (s, 2H), 3.11 (s, 2H), 2.21 (s, 3H).

3-Amino-3-(hydroxyimino)-N-[2-(hydroxyl)phenyl]propanamide 22. Compound 22 was synthesized from 71 in 53% yield exactly as described for the preparation of compound 7; off-white crystals; melting point 308–310 °C (dec.); UPLC retention time 1.17 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.85 (s, 1H), 9.29 (s, 1H), 9.12 (s, 1H), 7.88 (dd, *J* = 8.0, 1.6 Hz, 1H), 6.92 (dt, *J* = 7.6, 1.6 Hz, 1H), 6.85 (dd, *J* = 8.0, 1.2 Hz, 1H), 6.75 (dt, *J* = 8.0, 1.6 Hz, 1H), 5.60 (s, 2H), 3.12 (s, 2H).

3-Amino-3-(hydroxyimino)-N-[2-(mercapto)phenyl]propanamide 23. Compound 23 was synthesized from 72 in 65% yield exactly as described for the preparation of compound 7; light-gray crystals; melting point 324–325 °C (dec.); UPLC retention time 3.32 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.20 (s, 1H), 8.05 (dd, *J* = 8.0, 0.8 Hz, 1H), 7.94 (d, *J* = 8.0 Hz, 1H), 7.49 (dt, *J* = 7.6, 1.2 Hz, 1H), 7.41 (dt, *J* = 7.6, 1.2 Hz, 1H), 5.70 (s, 2H), 3.83 (s, 2H).

3-Amino-3-(hydroxyimino)-N-[2-(ethyl)phenyl]propanamide 24. Compound 24 was synthesized from 73 in 74% yield exactly as described for the preparation of compound 7; off-white crystals; melting point 266–268 °C (dec.); UPLC retention time 3.89 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.43 (s, 1H), 9.10 (s, 1H), 7.50 (d, *J* = 7.6 Hz, 1H), 7.21 (dd, *J* = 7.2, 1.2 Hz, 1H), 7.19–7.08 (m, 2H), 5.55 (s, 2H), 3.11 (s, 2H), 2.58 (q, *J* = 7.6 Hz, 2H), 1.12 (t, *J* = 7.6 Hz, 3H).

3-Amino-3-(hydroxyimino)-N-[2-(isopropyl)phenyl]propanamide 25. Compound 25 was synthesized from 74 in 64% yield exactly as described for the preparation of compound 7; tan crystals; melting point 228–230 °C (dec.); UPLC retention time 4.87 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.46 (s, 1H), 9.08 (s, 1H), 7.38 (dd, *J* = 8.0,

2.4 Hz, 1H), 7.30 (dd, *J* = 8.0, 2.8 Hz, 1H), 7.20–7.12 (m, 2H), 5.53 (s, 2H), 3.14 (septet, *J* = 6.8 Hz, 1H), 3.10 (s, 2H), 1.14 (d, *J* = 6.8 Hz, 6H).

3-Amino-3-(hydroxyimino)-N-[2-(phenyl)phenyl]propanamide 26. Compound 26 was synthesized from 75 in 77% yield exactly as described for the preparation of compound 7, except that the compound was isolated as the hydrochloride salt by dissolving it in ethyl acetate and adding HCl in ether; off-white solid; melting point 284–285 °C (dec.); UPLC retention time 6.01 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.71 (bs, 1H), 11.09 (s, 1H), 9.85 (s, 1H), 9.02 (bs, 1H), 8.73 (bs, 1H), 7.53–7.30 (m, 9H), 3.48 (s, 2H).

3-Amino-3-(hydroxyimino)-N-[2-(ethoxy)phenyl]propanamide 27. Compound 27 was synthesized from 76 in 59% yield exactly as described for the preparation of compound 7; off-white crystals; melting point 372–374 °C (dec.); UPLC retention time 3.85 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.28 (s, 1H), 9.14 (s, 1H), 8.11 (d, *J* = 8.0 Hz, 1H), 7.04–7.00 (m, 2H), 6.92–6.86 (m, 1H), 5.67 (s, 2H), 4.07 (q, *J* = 6.8 Hz, 2H), 3.14 (s, 2H), 1.14 (t, *J* = 6.8 Hz, 3H).

3-Amino-3-(hydroxyimino)-N-[2-(phenoxy)phenyl]propanamide 28. Compound 28 was synthesized from 77 in 79% yield exactly as described for the preparation of compound 7; white crystals; melting point 275–277 °C (dec.); UPLC retention time 6.40 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.63 (s, 1H), 9.05 (s, 1H), 8.13 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.39 (t, *J* = 8.0 Hz, 2H), 7.17–7.00 (m, 5H), 6.87 (dd, *J* = 8.0, 1.2 Hz, 1H), 5.51 (s, 2H), 3.11 (s, 2H).

3-Amino-3-(hydroxyimino)-N-[2-(trifluoromethyl)phenyl]propanamide 29. Compound 29 was synthesized from 78 in 67% yield exactly as described for the preparation of compound 7; pale-green crystals; melting point 280–281 °C (dec.); UPLC retention time 3.31 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.72 (s, 1H), 9.12 (s, 1H), 7.73 (d, *J* = 8.0 Hz, 1H), 7.70–7.65 (m, 2H), 7.45–7.39 (m, 1H), 5.56 (s, 2H), 3.13 (s, 2H). ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ –59.83 (s, 3F).

3-Amino-3-(hydroxyimino)-N-[2-(chloro)phenyl]propanamide 30. Compound 30 was synthesized from 79 in 69% yield exactly as described for the preparation of compound 7; off-white crystals; melting point 291–293 °C (dec.); UPLC retention time 2.66 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.80 (s, 1H), 9.16 (s, 1H), 7.96 (d, *J* = 8.4 Hz, 1H), 7.49 (d, *J* = 8.0 Hz, 1H), 7.33 (t, *J* = 8.0 Hz, 1H), 7.15 (t, *J* = 7.6 Hz, 1H), 5.63 (s, 2H), 3.18 (s, 2H).

3-Amino-3-(hydroxyimino)-N-[2-(bromo)phenyl]propanamide 31. Compound 31 was synthesized from 80 in 77% yield exactly as described for the preparation of compound 7; white crystals; melting point 278–280 °C (dec.); UPLC retention time 2.87 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.74 (s, 1H), 9.15 (s, 1H), 7.90 (d, *J* = 8.0 Hz, 1H), 7.65 (d, *J* = 8.0 Hz, 1H), 7.37 (t, *J* = 8.0 Hz, 1H), 7.10 (t, *J* = 7.6 Hz, 1H), 5.63 (s, 2H), 3.16 (s, 2H).

2-(3-Amino-3-(hydroxyimino)propanamido)benzamide 32. Compound 32 was synthesized from 81 in 50% yield exactly as described for the preparation of compound 7; tan crystals; melting point 320–321 °C (dec.); UPLC retention time 0.94 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.64 (s, 1H), 9.09 (s, 1H), 8.44 (d, *J* = 8.4 Hz, 1H), 8.23 (s, 1H), 7.77 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.67 (s, 1H), 7.48 (dt, *J* = 8.0, 1.2 Hz, 1H), 7.12 (dt, *J* = 7.6, 0.8 Hz, 1H), 5.52 (s, 2H), 3.06 (s, 2H).

2-(3-Amino-3-(hydroxyimino)propanamido)benzoate 33. Compound 33 was synthesized from 82 in 69% yield exactly as described for the preparation of compound 7; tan crystals; melting point 282–283 °C (dec.); UPLC retention time 5.45 min. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.75 (s, 1H), 9.16 (s, 1H), 8.36 (d, *J* = 8.4 Hz, 1H), 7.94 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.61 (dt, *J* = 8.0, 1.6 Hz, 1H), 7.19 (dt, *J* = 7.6, 1.2 Hz, 1H), 5.59 (s, 2H), 4.33 (q, *J* = 7.2 Hz, 2H), 3.12 (s, 2H), 1.33 (t, *J* = 7.2 Hz, 3H).

Expression and Purification of Recombinant Proteins and the Histone Demethylase Assay. Full-length human LSD1 cDNA was subcloned into the pET15b bacterial expression vector (Novagen, Madison, WI) in frame with an N-terminal 6× HIS-tag and transformed into the BL₂₁(DE₃) strain of *Escherichia coli*. Following selection, expression and purification of recombinant LSD1 protein were performed as previously described.⁸ Briefly, expression of LSD1-

HIS protein was induced by 1 mM isopropyl β -D-1-thiogalactopyranoside for 6 h at 25 °C. The HIS-tagged protein was purified using Ni-NTA affinity purification resin and column as recommended by the manufacturer (Qiagen, Valencia, California). Bound protein was eluted by imidazole, and the eluate was dialyzed in PBS at 4 °C. Enzymatic activity of LSD1 was examined using luminol-dependent chemiluminescence to measure the production of H_2O_2 , as previously described.⁴⁰ In brief, LSD1 activity was assayed in 50 mM Tris, pH 8.5, 50 mM KCl, 5 mM MgCl₂, 5 nmol of luminol, and 20 μ g/mL of horseradish peroxidase with the indicated concentrations of H3K4me2 (1–21 aa) peptide as substrate. The integral values were calibrated against standards containing known concentrations of H_2O_2 , and the activities expressed as pmols H_2O_2 /mg protein/min. Reaction mixtures were incubated with or without 5 μ g of purified LSD1 in 50 mM Tris, pH 8.5, 50 mM KCl, 5 mM MgCl₂, 0.5% BSA, and 5% glycerol for 3 h at 37 °C. This reaction mixture was analyzed by Western blotting using antibodies (Millipore) that specifically recognize the dimethyl group of H3K4.

Western Blotting. Cytoplasmic and nuclear fractions were prepared for Western blot analysis using the NE-PER Nuclear and Cytoplasmic Extraction Kit (Pierce, Rockford, IL). Primary antibodies against H3K4me2 were from Millipore. The pCNA monoclonal antibody was purchased from Oncogene Research Products (Cambridge, MA). Dye-conjugated secondary antibodies were used for quantification of Western blot results using the Odyssey infrared detection system and software (LI-COR Biosciences, Lincoln, NE). Determination of H3K4me2, SFRP2, HCAD, and GATA4 levels in the Calu-6 cell line were determined as previously reported.^{32,41}

RNA Isolation and qPCR. RNA was extracted using TRIzol reagents (Invitrogen, Carlsbad, CA). First-strand cDNA was synthesized using SuperScript III reverse transcriptase with an oligo(dT) primer (Invitrogen). qPCR was performed using the following primers: *SFRP2* sense, 5' AAG CCT GCA AAA ATA AAA ATG ATG; *SFRP2* antisense, 5' TGT AAA TGG TCT TGC TCT TGG TCT (annealing at 57.4 °C); *GATA4* sense, 5' GGC CGC CCG ACA CCC CAA TCT; *GATA4* antisense, 5' ATA GTG ACC CGT CCC ATC TCG (annealing at 64 °C). qPCR was performed in a MyiQ single color real-time PCR machine (Bio-Rad, Hercules, CA) with GAPDH as an internal control.

Determination of Cell Viability. Calu-6 human anaplastic nonsmall cell lung carcinoma cells were maintained in culture using RPMI medium plus 10% fetal bovine serum. For the (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) reduction assay, 4000 cells/well were seeded in 100 μ L of medium in a 96-well plate and the cells were allowed to attach at 37 °C in 5% CO₂ for one day. The medium was aspirated, and cells were treated with 100 μ L of fresh medium containing appropriate concentrations of each test compound. The cells were incubated for 4 days at 37 °C in 5% CO₂. After 4 days, 20 μ L of the MTS reagent solution (Promega CellTiter 96 Aqueous One Solution Cell Proliferation Assay) was added to the medium. The cells were incubated for another 2 h at 37 °C under 5% CO₂ environment. Absorbance was measured at 490 nm on a microplate reader equipped with SOFTmax PRO 4.0 software to determine the cell viability.

Molecular Modeling Studies. All molecular modeling studies were performed using the GOLD software package, version 5.1 (Cambridge Crystallographic Data Centre, Cambridge, UK). The X-ray coordinates of LSD1 (PDB code 2VID) were downloaded from the Protein Data Bank,⁵⁰ and the active site was defined as a sphere enclosing residues within 6 Å around the substrate-like peptide inhibitor cocrystal. The 3D structure of **22** was built using Chem 3D Pro software (version 12.0) and was energy minimized using MM2 force field for 1000 iterations and a convergence value of 0.001 kcal/mol/Å as the termination criterion. The energy minimized amidoxime **22** was docked in the binding site of LSD1 and scored using ChemScore.⁴⁹ All poses generated by the program were visualized; however, the pose with the highest fitness score was used for elucidating the binding characteristics of **22** in the LSD1 active site. The numbering sequence of amino acid residues in 2VID is preserved throughout this paper.

■ ASSOCIATED CONTENT

📄 Supporting Information

Results of in silico docking of amidoxime **22** in the active site of LSD1 without the bound CoREST co-repressor. Physical properties and inhibition of purified recombinant LSD1 following treatment with 10 μ M **3–33**, and fold increase in global H3K4me2 levels in Calu-6 human lung adenocarcinoma cells following treatment with carbamimidothioates **5**, **8**, and **9**, aromatic amines **6**, **10**, and **11** and amidoximes **7** and **12–33** at 10 μ M. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*Phone: 843-876-2453. Fax: 843-876-2353. E-mail: woster@musc.edu. Address: Medical University of South Carolina, 70 President Street, Drug Discovery Building Room 405, Charleston, South Carolina 29425.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

The research described in this manuscript was supported by NIH grant 1R01CA149095 (P.M.W.), 1R01CA98454 (R.A.C.), and 1R01CA51085 (R.A.C.) and by grants from the Samuel Waxman Cancer Research Foundation (R.A.C., P.M.W.) and the Susan B. Komen for the Cure Foundation (R.A.C.). In addition, a portion of this work was supported by a grant from Progen Pharmaceuticals, Ltd., Brisbane, Queensland, Australia (P.M.W., R.A.C.). R.A.C. also serves as a consultant to Progen Pharmaceuticals.

■ ABBREVIATIONS USED

LSD1, lysine-specific demethylase 1; H3K4me1, histone 3 methyllysine 4; H3K4me2, histone 3 dimethyllysine 4; JmjC, Jumonji C domain-containing demethylase; FAD, flavin adenine dinucleotide; MAO, monoamine oxidase; CoREST, RE1 silencing factor/neural restrictive silencing factor co-repressor protein; SFRP, secreted frizzled-related protein; HCAD, h-cadherin; qPCR, quantitative polymerase chain reaction; PCNA, proliferating cell nuclear antigen

■ REFERENCES

- (1) Marks, P. A.; Richon, V. M.; Breslow, R.; Rifkind, R. A. Histone deacetylase inhibitors as new cancer drugs. *Curr. Opin. Oncol.* **2001**, *13* (6), 477–483.
- (2) Luger, K.; Mader, A. W.; Richmond, R. K.; Sargent, D. F.; Richmond, T. J. Crystal structure of the nucleosome core particle at 2.8 Å resolution. *Nature* **1997**, *389* (6648), 251–260.
- (3) Zhang, L.; Eugeni, E. E.; Parthun, M. R.; Freitas, M. A. Identification of novel histone post-translational modifications by peptide mass fingerprinting. *Chromosoma* **2003**, *112* (2), 77–86.
- (4) Jenuwein, T.; Allis, C. D. Translating the histone code. *Science* **2001**, *293* (5532), 1074–1080.
- (5) Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. *Nature Rev. Drug Discovery* **2002**, *1* (4), 287–299.
- (6) Baylin, S. B.; Ohm, J. E. Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction? *Nature Rev. Cancer* **2006**, *6* (2), 107–116.
- (7) Jones, P. A.; Baylin, S. B. The epigenomics of cancer. *Cell* **2007**, *128* (4), 683–692.

- (8) Shi, Y.; Lan, F.; Matson, C.; Mulligan, P.; Whetstine, J. R.; Cole, P. A.; Casero, R. A.; Shi, Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. *Cell* **2004**, *119* (7), 941–953.
- (9) Whetstine, J. R.; Nottke, A.; Lan, F.; Huarte, M.; Smolnikov, S.; Chen, Z.; Spooner, E.; Li, E.; Zhang, G.; Colaiacovo, M.; Shi, Y. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. *Cell* **2006**, *125* (3), 467–481.
- (10) Tsukada, Y.; Zhang, Y. Purification of histone demethylases from HeLa cells. *Methods* **2006**, *40* (4), 318–326.
- (11) Huarte, M.; Lan, F.; Kim, T.; Vaughn, M. W.; Zaratiegui, M.; Martienssen, R. A.; Buratowski, S.; Shi, Y. The fission yeast Jmj2 reverses histone H3 lysine 4 tri-methylation. *J. Biol. Chem.* **2007**, *282*, 21662–21670.
- (12) Varier, R. A.; Timmers, H. T. Histone lysine methylation and demethylation pathways in cancer. *Biochim. Biophys. Acta* **2011**, *1815* (1), 75–89.
- (13) Bannister, A. J.; Kouzarides, T. Reversing histone methylation. *Nature* **2005**, *436* (7054), 1103–1106.
- (14) Jenuwein, T. The epigenetic magic of histone lysine methylation. *FEBS J.* **2006**, *273* (14), 3121–3135.
- (15) Schneider, R.; Bannister, A. J.; Kouzarides, T. Unsafe SETs: histone lysine methyltransferases and cancer. *Trends Biochem. Sci.* **2002**, *27* (8), 396–402.
- (16) Wilson, J. R.; Jing, C.; Walker, P. A.; Martin, S. R.; Howell, S. A.; Blackburn, G. M.; Gambelin, S. J.; Xiao, B. Crystal structure and functional analysis of the histone methyltransferase SET7/9. *Cell* **2002**, *111* (1), 105–115.
- (17) Kouzarides, T. Histone methylation in transcriptional control. *Curr. Opin. Genet. Dev.* **2002**, *12* (2), 198–209.
- (18) Martin, C.; Zhang, Y. The diverse functions of histone lysine methylation. *Nature Rev. Mol. Cell Biol.* **2005**, *6* (11), 838–849.
- (19) Zhang, Y.; Reinberg, D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. *Genes Dev.* **2001**, *15* (18), 2343–2360.
- (20) Liang, G.; Lin, J. C.; Wei, V.; Yoo, C.; Cheng, J. C.; Nguyen, C. T.; Weisenberger, D. J.; Egger, G.; Takai, D.; Gonzales, F. A.; Jones, P. A. Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. *Proc. Natl. Acad. Sci. U.S.A.* **2004**, *101* (19), 7357–7362.
- (21) Schneider, R.; Bannister, A. J.; Myers, F. A.; Thorne, A. W.; Crane-Robinson, C.; Kouzarides, T. Histone H3 lysine 4 methylation patterns in higher eukaryotic genes. *Nature Cell Biol.* **2004**, *6* (1), 73–77.
- (22) Lee, M. G.; Wynder, C.; Schmidt, D. M.; McCafferty, D. G.; Shiekhhattar, R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. *Chem. Biol.* **2006**, *13* (6), 563–567.
- (23) Huang, Y.; Greene, E.; Murray Stewart, T.; Goodwin, A. C.; Baylin, S. B.; Woster, P. M.; Casero, R. A., Jr. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. *Proc. Natl. Acad. Sci. U.S.A.* **2007**, *104* (19), 8023–8028.
- (24) Stavropoulos, P.; Hoelz, A. Lysine-specific demethylase 1 as a potential therapeutic target. *Expert Opin. Ther. Targets* **2007**, *11* (6), 809–820.
- (25) Schmidt, D. M.; McCafferty, D. G. *trans*-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. *Biochemistry* **2007**, *46* (14), 4408–4416.
- (26) Culhane, J. C.; Szweczek, L. M.; Liu, X.; Da, G.; Marmorstein, R.; Cole, P. A. A mechanism-based inactivator for histone demethylase LSD1. *J. Am. Chem. Soc.* **2006**, *128* (14), 4536–4537.
- (27) Shao, G. B.; Ding, H. M.; Gong, A. H. Role of histone methylation in zygotic genome activation in the preimplantation mouse embryo. *In Vitro Cell. Dev. Biol.: Anim.* **2008**, *44* (3–4), 115–120.
- (28) Ueda, R.; Suzuki, T.; Mino, K.; Tsumoto, H.; Nakagawa, H.; Hasegawa, M.; Sasaki, R.; Mizukami, T.; Miyata, N. Identification of cell-active lysine specific demethylase 1-selective inhibitors. *J. Am. Chem. Soc.* **2009**, *131* (48), 17536–17537.
- (29) Binda, C.; Valente, S.; Romanenghi, M.; Pilotto, S.; Cirilli, R.; Karytinis, A.; Ciossani, G.; Botrugno, O. A.; Forneris, F.; Tardugno, M.; Edmondson, D. E.; Minucci, S.; Mattevi, A.; Mai, A. Biochemical, Structural, and Biological Evaluation of Tranylcyproamine Derivatives as Inhibitors of Histone Demethylases LSD1 and LSD2. *J. Am. Chem. Soc.* **2010**, *132*, 6827–6833.
- (30) Ogasawara, D.; Suzuki, T.; Mino, K.; Ueda, R.; Khan, M. N.; Matsubara, T.; Koseki, K.; Hasegawa, M.; Sasaki, R.; Nakagawa, H.; Mizukami, T.; Miyata, N. Synthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitor. *Bioorg. Med. Chem.* **2011**, *19* (12), 3702–3708.
- (31) Ueda, R.; Suzuki, T.; Mino, K.; Tsumoto, H.; Nakagawa, H.; Hasegawa, M.; Sasaki, R.; Mizukami, T.; Miyata, N. Identification of cell-active lysine specific demethylase 1-selective inhibitors. *J. Am. Chem. Soc.* **2009**, *131* (48), 17536–17537.
- (32) Huang, Y.; Greene, E.; Stewart, T. M.; Goodwin, A. C.; Baylin, S. B.; Woster, P. M.; Casero, R. A. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. *Proc. Natl. Acad. Sci. U.S.A.* **2007**, *104*, 8023–8028.
- (33) Huang, Y.; Stewart, T. M.; Wu, Y.; Baylin, S. B.; Marton, L. J.; Perkins, B.; Jones, R. J.; Woster, P. M.; Casero, R. A., Jr. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. *Clin. Cancer Res.* **2009**, *15* (23), 7217–7228.
- (34) Suzuki, T.; Miyata, N. Lysine demethylases inhibitors. *J. Med. Chem.* **2011**, *54* (24), 8236–8250.
- (35) Bi, X.; Lopez, C.; Bacchi, C. J.; Rattendi, D.; Woster, P. M. Novel alkylpolyaminoguanidines and alkylpolyaminobiguanides with potent antitrypanosomal activity. *Bioorg. Med. Chem. Lett.* **2006**, *16* (12), 3229–3232.
- (36) Karginov, V. A.; Nestorovich, E. M.; Yohannes, A.; Robinson, T. M.; Fahmi, N. E.; Schmidtman, F.; Hecht, S. M.; Bezrukov, S. M. Search for cyclodextrin-based inhibitors of anthrax toxins: synthesis, structural features, and relative activities. *Antimicrob. Agents Chemother.* **2006**, *50* (11), 3740–3753.
- (37) Ji, J. S.; Chen, M. J.; Wang, Q. W.; Sheng, W. 1,3-Dinitro-2-chloro-5-trifluorotoluene and its bridged derivatives I. An investigation on the displacement reactions of bidentate nucleophiles towards aromatic rings. *Chin. J. Chem.* **1991**, *9*, 343–350.
- (38) Fecher, A.; Fretz, H.; Hilpert, K.; Riederer, M. Preparation of indolyl acetic acid derivatives as CRTH2 receptor inhibitors. PCT Int. Application WO 2005094816, 2005.
- (39) Hyatt, J. A. Neber rearrangement of amidoximesulfonates. Synthesis of 2-amino-1-azirines. *J. Org. Chem.* **1981**, *46*, 3953–3955.
- (40) Wang, Y.; Murray-Stewart, T.; Devereux, W.; Hacker, A.; Frydman, B.; Woster, P. M.; Casero, R. A., Jr. Properties of purified recombinant human polyamine oxidase, PAOh1/SMO. *Biochem. Biophys. Res. Commun.* **2003**, *304* (4), 605–611.
- (41) Sharma, S.; Wu, Y.; Steinbergs, N.; Crowley, M.; Hanson, A.; Casero, R. A. J.; Woster, P. (Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators. *J. Med. Chem.* **2010**, *53* (14), 5197–5212.
- (42) Chen, Y.; Yang, Y.; Wang, F.; Wan, K.; Yamane, K.; Zhang, Y.; Lei, M. Crystal structure of human histone lysine-specific demethylase 1 (LSD1). *Proc. Natl. Acad. Sci. U.S.A.* **2006**, *103* (38), 13956–13961.
- (43) Lee, M. G.; Wynder, C.; Cooch, N.; Shiekhhattar, R. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. *Nature* **2005**, *437* (7057), 432–435.
- (44) Andres, M. E.; Burger, C.; Peral-Rubio, M. J.; Battaglioli, E.; Anderson, M. E.; Grimes, J.; Dallman, J.; Ballas, N.; Mandel, G. CoREST: a functional corepressor required for regulation of neural-specific gene expression. *Proc. Natl. Acad. Sci. U.S.A.* **1999**, *96* (17), 9873–9878.
- (45) Jiang, G. X.; Liu, W.; Cui, Y. F.; Zhong, X. Y.; Tai, S.; Wang, Z. D.; Shi, Y. G.; Li, C. L.; Zhao, S. Y. Reconstitution of secreted frizzled-related protein 1 suppresses tumor growth and lung metastasis in an orthotopic model of hepatocellular carcinoma. *Dig. Dis. Sci.* **2010**, *55* (10), 2838–2843.

(46) Toyooka, S.; Toyooka, K. O.; Harada, K.; Miyajima, K.; Makarla, P.; Sathyanarayana, U. G.; Yin, J.; Sato, F.; Shivapurkar, N.; Meltzer, S. J.; Gazdar, A. F. Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas. *Cancer Res.* **2002**, *62* (12), 3382–3386.

(47) Wu, L. P.; Wang, X.; Li, L.; Zhao, Y.; Lu, S.; Yu, Y.; Zhou, W.; Liu, X.; Yang, J.; Zheng, Z.; Zhang, H.; Feng, J.; Yang, Y.; Wang, H.; Zhu, W. G. Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. *Mol. Cell. Biol.* **2008**, *28* (10), 3219–3235.

(48) Huang, Y.; Murray-Stewart, T.; Wu, Y.; Baylin, S. B.; Marton, L. J.; Woster, P. M.; Casero, J., R.A. Novel oligoamine analogues inhibit lysine-specific demethylase 1 (LSD1) and induce re-expression of epigenetically silenced genes. *Cancer Chemother. Pharmacol.* **2009**, *15*, 7217–7228.

(49) Jones, G.; Willett, P.; Glen, R. C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. *J. Mol. Biol.* **1995**, *245* (1), 43–53.

(50) Forneris, F.; Binda, C.; Adamo, A.; Battaglioli, E.; Mattevi, A. Structural basis of LSD1-CoREST selectivity in histone H3 recognition. *J. Biol. Chem.* **2007**, *282* (28), 20070–20074.

(51) Wang, J.; Lu, F.; Ren, Q.; Sun, H.; Xu, Z.; Lan, R.; Liu, Y.; Ward, D.; Quan, J.; Ye, T.; Zhang, H. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. *Cancer Res.* **2011**, *71* (23), 7238–7249.

(52) Sharma, S. K.; Hazeldine, S.; Crowley, M. L.; Hanson, A.; Beattie, R.; Varghese, S.; Sennanayake, T. M. D.; Hirata, A.; Hirata, F.; Huang, Y.; Wu, Y.; Steinbergs, N.; Murray-Stewart, T.; Bytheway, I.; Casero, J., R. A.; Woster, P. M. Polyamine-based small molecule epigenetic modulators. *MedChemComm* **2011**, ePub ahead of print. DOI: 10.1039/c1031md00220a.

(53) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv. Drug Delivery Rev.* **2001**, *46* (1–3), 3–26.

(54) Bellevue, F. H., III; Boahbedason, M.; Wu, R.; Woster, P. M.; Casero, J. R. A.; Rattendi, D.; Lane, S.; Bacchi, C. J. Structural comparison of alkylpolyamine analogues with potent in vitro antitumor or antiparasitic activity. *Bioorg. Med. Chem. Lett.* **1996**, *6* (22), 2765–2770.